M. Levine
Endocrinology, Diabetes and Metabolism · 2017
A researcher in the Science corpus: 1 paper; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Endocrinology, Diabetes and Metabolism — 11 citations into it
- Surgery — 6 citations into it
Whom M. Levine trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from M. Levine's perspective
Ordered by how strongly the researchers M. Levine trusts endorse each paper. Same corpus, a different order for every researcher.
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study (British medical journal)
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition (Diabetes Care)
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of… (Diabetes Care)
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. (New England Journal of Medicine)
- Biology of human sodium glucose transporters. (Physiological Reviews)
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus (Circulation)
- Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications (Diabetic Medicine)
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors (Diabetes Care)
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial (European Heart Journal)
- Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes… (Diabetes Care)
Their papers
- Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials (2017) — 135 citations